Drug Trial Radar · NCT01909453
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
921
Actual
Start
Sep 12, 2013
Primary completion
Nov 9, 2016
Study completion Sep 3, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized. Part 1: Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms: 1. LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm) 2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or 3. vemurafenib 960 mg BID (denoted as vemurafenib arm) Part 2: Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms: 1. LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or 2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm)
Conditions
- Melanoma
Interventions
LGX818Drug
LGX818- Orally 100 mg and 50 mg capsules
MEK162Drug
MEK162- Orally 15 mg tablets
vemurafenibDrug
Tablets in bottles or blisters 240 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib GroupTime frame: From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months)
- Part 1: PFS by BIRC in Combo 450 Group as Compared to LGX818 GroupTime frame: From randomization until documented PD, initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months), excluding Part 1: LGX818 300 mg group; up to 35 months for Part 1: LGX 300 mg group
Locations
282 sites in 29 countries. Site status is shown where the registry gives one.
Retinal Consultants of Alabama P.C.
Birmingham, Alabama
UAB Callahan Eye Hospital
Birmingham, Alabama
UAB Comprehensive Cancer Center
Birmingham, Alabama
UAB The Kirklin Clinic
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Oncology Associates
Tucson, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
Highlands Oncology Group
Rogers, Arkansas
Highlands Oncology Group - Fayetteville
Springdale, Arkansas
UC Irvine Medical Center
Orange, California
Rocky Mountain Cancer Centers (Williams) - USOR
Aurora, Colorado
Rocky Mountain Cancer Centers
Boulder, Colorado
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Rocky Mountain Cancer Centers (Williams) - USOR
Denver, Colorado
Rocky Mountain Cancer Centers
Lakewood, Colorado
Specialty Eye Care
Parker, Colorado
Rocky Mountain Cancer Centers
Pueblo, Colorado
University Cancer Institute
Boynton Beach, Florida
University of Miami
Miami, Florida
Eye & Ear Infirmary- Opthalmology
Chicago, Illinois
University of Illinois at Chicago
Chicago, Illinois
University of Illinois Hospital and Health Sciences System - Investigational Drug Service
Chicago, Illinois
University of Illinois Hospital and Health Sciences System
Chicago, Illinois
University of Illinois Medical Center
Chicago, Illinois
Oncology Specialists, SC
Niles, Illinois
Goshen Center For Cancer Care
Goshen, Indiana
Lack's Cancer Center at Mercy Health Saint Mary's
Grand Rapids, Michigan
Mercy Health Hauenstein Neuroscience Center Neuro-Ophthalmology (Clinic)
Grand Rapids, Michigan
Retina Specialists of Michigan
Grand Rapids, Michigan
Hattiesburg Clinic Oncology Hem
Hattiesburg, Mississippi
Jackson Oncology Associates - St. Dominic Hospital
Jackson, Mississippi
Nebraska Methodist Hospital
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Investigational Drug Service, Department of Pharmacy (Investigational Product)
Rochester, New York
University of Rochester Medical Center - PPDS
Rochester, New York
Tulsa Cancer Institute PLLC
Tulsa, Oklahoma
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Sanford Cancer Center Oncology Clinic & Pharmacy
Sioux Falls, South Dakota
University of Tennessee Medical Center Cancer Institute
Knoxville, Tennessee
Showing 40 of 282 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.